| Ticker: TKTX | 195 Allbany Street | |
| Exchange: NASDAQ-National Market | Cambridge, Massachusetts 02139 | |
| Industry: Manufacturing | (617) 349-0200 |
| Type of Shares: | Common Shares | Filing Date: | 8/27/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 10/16/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $15.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.05 | |
| Offering Amount: | $35,000,000 | Selling: | $0.63 | |
| Expenses: | $790,000 | Reallowance: | $0.10 | |
| Shares Out After: | 16,616,415 |
| Manager | Tier | Phone |
| Morgan Stanley & Co. Incorporated | Lead Manager | (212) 703-4797 |
| Pacific Crest Securities Inc. | Co-manager | (503) 248-0721 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $15.40 | $1.98 | $11.70 | Assets: | $33.63 |
| Net Income: | $2.07 | -$5.99 | $5.11 | Liabilities: | $5.74 |
| EPS: | $0.14 | -$0.42 | $0.35 | Equity: | $27.89 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company has developed two proprietary technology platforms, Gene Activation and gene therapy. The company's Gene's Activation technology is a proprietary approach to the large scale production of therapeutic proteins which does not require the cloning of genes and their subsequent insertion into non-human cell lines. Consequently, the company believes its Gene Activation technology avoids using patented approaches to protein production associated with such conventional genetic engineering which have served as effective barriers to competition in the $11 billion therapeutic protein market. As a result, the company believes it will be able to develop and successfully commercialize a broad range of gene activated approval from regulatory authorities and generated significant revenues in major markets. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research, preclinical and clinical product development, and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.